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represent the official position of the Centers for Disease Control and Prevention. 
Overview 
 Virology and transmission 
 Clinical presentation 
 Laboratory diagnosis 
 Management and prevention 
 Public health surveillance 
 
West Nile virus (WNV) 
 
Virus genus: Flavivirus 
Transmission: Mosquito-borne 
Amplifying host:  Birds 
Global distribution: Worldwide 
U.S. geographic foci: 
New York in 1999  
spread nationwide 






Person-to-person transmission of WNV 
• Blood transfusion 
• Organ transplantation 
• Intrauterine 
• Breastfeeding 
Replication in dendritic cells at inoculation site 
 




Invasion of central nervous system 
Pathogenesis of human WNV infection 
Neuroinvasive disease* (<1%) 
Asymptomatic infection (70-
80%) 
Febrile illness (20-30%) 
*Infections of central nervous system such as meningitis, encephalitis, or myelitis 
Clinical spectrum of human WNV infections 
WNV non-neuroinvasive disease 
 Incubation period 2-14 days 
 Non-specific febrile illness  
 Usually resolves within a week 
 Some symptoms may persist for weeks or months 
 Overall case fatality <1% 
 
WNV neuroinvasive disease 
 Meningitis, encephalitis, and acute flaccid paralysis (AFP) 
 Most cases require hospitalization 
 Many patients with encephalitis or AFP have sequelae 
 50-75% need assisted living or rehabilitation 
 Morbidity and mortality higher in elderly 
 Overall case fatality 10% 
 
Risk factors for severe disease 
 Age>60 years 
 Diabetes 
 Hypertension 
 Cancer history 
 Chronic renal disease 
 Chronic alcohol abuse 
 
Lindsey, N.P., Am J Trop Med Hyg. 2012; 87(1): 179–184 
 
WNV RNA in urine 
 In 2010, one study found WNV RNA in urine of 5 (20%) 
of 25 patients who had acute WNV disease 1-7 years 
earlier 
 Two subsequent studies of 103 persons infected with 
WNV several weeks to 7 years prior; only one (<1%) 
with RNA in urine 
 Possible reasons for discrepancy: 
 Differences in test performance 
 Different study cohorts with different incidence WNV in urine 
 Shedding of WNV RNA may be intermittent 
 
Murray K et al. J Infect Dis. 2010; 201:2–4. Gibney KB et al. J Infect Dis. 2011; 203:344–7. Baty SA et al. J Infect Dis. 2012;  
 
WNV infection and renal disease 
 Recent publication found relationship between WNV 
neuroinvasive disease and risk of developing of kidney 
disease 
 People with chronic kidney disease, diabetes, and 
hypertension are at increased risk of developing WNV 
neuroinvasive disease 
 Unclear cause and effect relationship between severe 
WNV and chronic kidney disease 
 Further study is need to determine what role WNV 
infections may have in subsequent kidney disease 
 
Nolan MS et al. PLoS One, published online July 6, 2012 
 
Days post illness onset 
      
IgM 
IgG Viremia 
WNV infection and antibody dynamics 
Symptom 
onset 
WNV antibody testing 
 IgM antibodies in serum or CSF 
 Performed by commercial and public health laboratories 
 Provides presumptive diagnosis of recent WNV infection 
 IgG antibodies in serum or CSF 
 Performed by commercial and public health laboratories 
 Suggest past flavivirus infection 
 Plaque reduction neutralization test (PRNT) 
 Performed predominantly in public health laboratories 
 Confirms specificity of IgM and IgG antibodies 
 
Limitations of WNV antibody testing 
 Serum collected <7 days of onset may lack detectable 
IgM 
 IgM can persist >1 year, positive result may = past 
infection 
 IgG only indicates past infection 
 Both IgM or IgG tests may be false-positive due to cross-
reactive antibodies to closely related flavivirus 
 Blood products can contain WNV Ab; complicate 
interpretation 
 
WNV molecular testing 
 WNV RNA in serum or CSF 
 Performed by commercial and public health 
laboratories 
 Indicates recent WNV infection 
 Low sensitivity as viral RNA is usually absent by time of 
symptom onset 
 May be useful in immunocompromised patients  
 
WNV disease treatment 
 Supportive care and management of complications 
 
 No proven antiviral or adjunctive therapy 
 
 Case reports or trials with several therapies 
 
 No ongoing trials or products for compassionate use 
 

Prevention of human WNV infections 
 No WNV vaccine licensed for use in humans 
 
 Community mosquito control programs 
 Use of larvicides, adulticides, and larvae-eating fish 
 
 Household and personal protective measures 
 Use air conditioning and install window/door screens 
 Reduce mosquito breeding sites 
 Wear long-sleeved shirts and long pants 
 Apply insect repellents 
 Limit outdoor exposure during peak biting times 
 
 Screen and remove infected blood products 
 
Transfusion-associated WNV infections 
 First documented in 2002 
 
 Routine screen of blood supply for WNV started in 2003 
 >2,500 infected products removed from blood supply 
 
 Rare transfusion-associated events still occur 
 Testing of pooled sample can fail to detect low viremic units 
 Some products are not screened (e.g. granulocytes) 
 
Transplant-associated WNV infections 
 Since 2002, roughly one transplant-associated WNV 
cluster recognized each year 
 
 Recipients at increased risk of severe disease  
 
 Organ donor screening practices for WNV vary 
 Screening is not mandatory 
 Concern for false-positive tests leading to organ wasting 
 Current screening techniques may fail to detect positive donors 
 
Arboviral surveillance 
 ArboNET is unique surveillance system 
 Human disease cases, viremic blood donors, veterinary cases, dead 
birds, mosquitoes, and sentinel animals 
 
 Data are updated weekly on CDC website 
 www.cdc.gov/ncidod/dvbid/westnile/index.htm 
 
 WNV is nationally notifiable disease 
 Clinicians and laboratories required to report WNV disease cases to 
local health department 
 
Average annual incidence of WNV neuroinvasive 
disease by county − United States, 1999-2011 
Number of WNV neuroinvasive disease cases by week 























Illness onset by week number 
Average annual incidence of WNV neuroinvasive 


























Age group (years) 
WNV neuroinvasive disease incidence by age group 



































Lindsey NP et al. MMWR  2010; 59(No. SS-2): 1-17 
Demographic and outcome data for WNV disease cases by 
clinical syndrome − United States, 1999-2011 
Fever Meningitis Encephalitis AFP 
(N=17,344) (N=4,469) (N=8,345) (N=429) 
Male 53% 55% 60% 64% 
Median Age 48 yrs 48 yrs 64 yrs 57 yrs 
Hospitalized* 21% 84% 90% 86% 
Died <1% 2% 12% 11% 
* Includes data from 2004-2011 
Annual number of neuroinvasive domestic arboviral diseases 
cases − United States, 1999-2011 
   Cases per year 
Virus Median (Range) 
West Nile 689 (19 - 2,946) 
La Crosse 73 (46 - 167) 
St. Louis encephalitis 8 (2 - 79) 
Eastern equine encephalitis 6 (3 - 21) 
Powassan 1 (0 - 12) 
Estimated numbers of human WNV infections and 
disease cases − United States, 1999-2011 
 31,414 WNV disease cases reported to CDC 
 
 Most cases are not diagnosed and reported 
 
 Extrapolating from serosurvey and surveillance data 
 400,000 - 950,000 cases of WNV disease may have occurred in the 
United States from 1999 through 2011 
 
Average annual incidence of WNV neuroinvasive 

















































































* Reported as of August 28, 2012 
Preliminary WNV surveillance data for 2012  
(as of 08/28/2012) 
 48 states have reported WNV activity (people, birds, 
mosquitoes)  
 1,590 cases of WNV disease in people, including 66 
deaths 
 889 (56%) neuroinvasive disease  
 701 (44%) non-neuroinvasive disease  
 70% of cases reported from six states (TX, SD, MS, OK, 
LA, MI) 
 45% of all cases reported from Texas 
 Currently highest number of WNV disease cases 
reported through last week in August since 1999 
 
Summary 
 WNV remains an important cause of neurologic 
infections in the United States 
 Seasonal outbreaks occur annually but are often quite 
focal and unpredictable in size and location 
 No proven effective treatments or vaccines 
 Diagnosis still important to: 
 Stop unnecessary therapies (e.g., antibiotics) 
 Limit further diagnostic evaluation 
 Help predict patient outcomes 
 Direct public health prevention measures 
 
Recommendations for healthcare providers 
 Consider WNV and other arboviral infections in the 
differential diagnosis of patients with aseptic 
meningitis or encephalitis 
 
 Obtain appropriate specimens for laboratory testing 
 
 Promptly report cases to state or local health 
departments to allow for appropriate control measures 
 
Thank you 
   Centers for Disease Control and Prevention   
Atlanta, Georgia 
 
Thank you for joining! 
Please email us questions at 









Join Us on Facebook 
 CDC Facebook page for 
Health Partners! “Like” our 
page today to receive COCA 
updates, guidance, and 
situational awareness about 
preparing for and responding 
to public health emergencies.  
 
 
 
 
 http://www.facebook.com/CDCHealthPartnersOutreach 
